Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Davis

Physician Assistant, Medical Phoenix, AZ Physician Assistant

NPI 1487103719 CMS profile 10538222

740 E Highland Ave, Suite 101, Phoenix, AZ 85014

Open in the dashboard

General payments

$10,302

497 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Davis of Phoenix, AZ is reported in the CMS Open Payments database as having received $10,302 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,653 120
2024 General $2,594 140
2023 General $1,702 69
2022 General $1,948 99
2021 General $1,406 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Davis
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Michelle Davis were reported at $2,653. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Michelle Davis Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,406 $156 $41–$563 $132
2022 $1,948 $185 $55–$649 $149
2023 $1,702 $199 $58–$717 $160
2024 $2,594 $206 $62–$740 $164
2025 $2,653 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,214 95 payments
  2. Regeneron Healthcare Solutions, Inc. $1,013 38 payments
  3. Genzyme Corporation $961 40 payments
  4. Sun Pharmaceutical Industries Inc. $779 38 payments
  5. LEO Pharma Inc. $686 29 payments
  6. Janssen Biotech, Inc. $686 34 payments
  7. Novartis Pharmaceuticals Corporation $590 33 payments
  8. UCB, Inc. $482 23 payments
  9. Incyte Corporation $331 16 payments
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $327 19 payments
  11. Other $2,233 132 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,817 491 payments
  2. Education $485 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,242 49 payments
  2. SKYRIZI $1,044 45 payments
  3. RINVOQ $733 30 payments
  4. DUPIXENT Inflammation And Immunology $726 28 payments
  5. ADBRY $586 25 payments
  6. TREMFYA $458 17 payments
  7. ILUMYA $410 28 payments
  8. VTAMA $399 45 payments
  9. Bimzelx $372 17 payments
  10. OPZELURA $331 16 payments
  11. Other $5,962 313 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

594

Median for Physician Assistant: 241

Drug cost

$66,084

Median for Physician Assistant: $4,110

Branded share of claims

5.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 13 $49,699
Clobetasol Propionate Generic 144 $5,310
Fluorouracil Generic 42 $3,115
Ketoconazole Generic 131 $1,937
Tretinoin Generic 26 $1,154
Metronidazole Generic 27 $1,123
Doxycycline Monohydrate Generic 32 $905
Clindamycin Phosphate Generic 17 $659
Triamcinolone Acetonide Generic 44 $588
Imiquimod Generic 16 $485

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$73,944

Medicare's payments for the services billed

Medicare patients

458

Average age 74

Services billed

2,142

272 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 49%
Ischemic heart disease 22%
Osteoporosis 20%
Cancer 17%
Diabetes 16%
Atrial fibrillation 15%
Chronic kidney disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $287
  • Regeneron Healthcare Solutions, Inc. $195
$482 13 —
SKYRIZI
  • AbbVie, Inc. $388
$388 — —
VTAMA
  • Dermavant Sciences, Inc. $260
$260 — —
RINVOQ
  • AbbVie, Inc. $186
$186 — —
ADBRY
  • LEO Pharma Inc. $185
$185 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record